Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Stopped Due to lack of clinical efficacy and lack of drug supply, trial was closed early and correlative studies were not pursued further.
Conditions
- Recurrent Melanoma
- Stage IV Skin Melanoma
Interventions
- BIOLOGICAL: NA17.A2 Peptide Vaccine
- BIOLOGICAL: Recombinant MAGE-3.1 Antigen
- BIOLOGICAL: Recombinant Interleukin-12
- BIOLOGICAL: MART-1 Antigen
- OTHER: Laboratory Biomarker Analysis
Sponsor
National Cancer Institute (NCI)